UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000048656 |
|---|---|
| Receipt number | R000055444 |
| Scientific Title | Multicenter Retrospective Study to Evaluate Necitumumab plus Cisplatin/Gemcitabine after Immune-check-point inhibitors in Advanced Squamous-Cell Lung Cancer in Japan (NINJA study) |
| Date of disclosure of the study information | 2022/08/12 |
| Last modified on | 2024/07/02 11:35:14 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Multicenter Retrospective Study to Evaluate Necitumumab plus Cisplatin/Gemcitabine after Immune-check-point inhibitors in Advanced Squamous-Cell Lung Cancer in Japan (NINJA study)
Acronym
Multicenter Retrospective Study to Evaluate Necitumumab plus Cisplatin/Gemcitabine after Immune-check-point inhibitors in Advanced Squamous-Cell Lung Cancer in Japan (NINJA study)
Scientific Title
Multicenter Retrospective Study to Evaluate Necitumumab plus Cisplatin/Gemcitabine after Immune-check-point inhibitors in Advanced Squamous-Cell Lung Cancer in Japan (NINJA study)
Scientific Title:Acronym
Multicenter Retrospective Study to Evaluate Necitumumab plus Cisplatin/Gemcitabine after Immune-check-point inhibitors in Advanced Squamous-Cell Lung Cancer in Japan (NINJA study)
Region
| Japan |
Condition
Condition
advanced metastatic or recurrent Squamous-cell lung cancer
Classification by specialty
| Pneumology | Hematology and clinical oncology |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
Efficacy
Basic objectives2
Safety
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Progression-free survival (PFS)
Key secondary outcomes
Overall survival (OS)
Time to Treatment Failure (TTF)
Objective response rate (ORR)
Disease control rate (DCR)
Safety
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Histological or cytological diagnosis of Squamous-cell lung cancer
Aged 20 years or older
Advanced metastatic or recurrent stage
Patients who received GCN therapy between 1 Nov. 2019 to 31 Mar. 2022
Patients who received ICIs before GCN therapy
Patients who received GCN therapy by 4th line
Key exclusion criteria
Patients who received GCN therapy after 5th line
Patients who participated in NESSIE trial (jRCTs051200138)
Target sample size
60
Research contact person
Name of lead principal investigator
| 1st name | Nobuhiko |
| Middle name | |
| Last name | Seki |
Organization
Department of Internal Medicine, Teikyo University School of Medicine
Division name
Division of Medical Oncology
Zip code
173-8605
Address
2-11-1 Kaga Itabashi-ku, Tokyo
TEL
03-3964-1211
nseki@med.teikyo-u.ac.jp
Public contact
Name of contact person
| 1st name | Shigeru |
| Middle name | |
| Last name | Tanzawa |
Organization
Department of Internal Medicine, Teikyo University School of Medicine
Division name
Division of Medical Oncology
Zip code
173-8605
Address
2-11-1 Kaga Itabashi-ku, Tokyo
TEL
03-3964-1211
Homepage URL
s.tanzawa@med.teikyo-u.ac.jp
Sponsor or person
Institute
Teikyo University
Institute
Department
Personal name
Funding Source
Organization
Nippon Kayaku Co.,Ltd
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Teikyo University Ethical Review Board for Medical and Health Research Involving Human Subjects
Address
2-11-1 Kaga Itabashi-ku, Tokyo
Tel
03-3964-1211
turb-office@teikyo-u.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2022 | Year | 08 | Month | 12 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2021 | Year | 12 | Month | 02 | Day |
Date of IRB
| 2022 | Year | 08 | Month | 10 | Day |
Anticipated trial start date
| 2022 | Year | 08 | Month | 12 | Day |
Last follow-up date
| 2022 | Year | 09 | Month | 30 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Multicenter Retrospective Study
Management information
Registered date
| 2022 | Year | 08 | Month | 12 | Day |
Last modified on
| 2024 | Year | 07 | Month | 02 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000055444
